AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00859638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: group self-management classes
Study NCT00859638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Occupational Therapy
Description: group self-management classes
Study NCT00859638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Capacity Building
Description: workshops and case reviews with primary health care team members
Study NCT01713933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulthera® System
Description: Focused ultrasound energy delivered below the surface of the skin.
Study NCT01488123 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individualized manualized Ayurvedic intervention
Description: The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
Study NCT00146159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: dosage
Study NCT00791973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone furoate
Description: 2 puffs in each nostril once daily for 1 week
Study NCT00791973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: 2 puffs in each nostril once daily for 1 week
Study NCT00977301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fosamprenavir/ritonavir
Description: 16 days 700mg/100mg RTV BID
Study NCT00977301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine
Description: 15 mg olanzapine single dose
Study NCT00977301 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Description: 10 mg olanzapine single dose
Study NCT04371874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide, Captopril, Nitrendipine, Aspirin
Description: The participants were grouped into a control group and a TDP group. Hypertension of patients in the control group was managed with the original protocol by doctors in village clinics. Patients in the TDP group were supplied with the TDP treatment, for whom different levels of oral administration plans to patients without drugs treatment in original protocol were: G 0 and G I, nifedipine (20mg, bid) or captopril (25mg, tid), hydrochlorothiazide (12.5mg, bid) for patients who couldn't tolerate previous drugs; G II, nifedipine (20mg, bid) plus hydrochlorothiazide (12.5mg, bid), or captopril (25mg, tid) plus hydrochlorothiazide (12.5mg, bid ), triple therapy for patients whose blood pressure did not reach target BP; G III, three drugs combination. Patients with drugs treatments in the original protocol were changed to be treated with the above antihypertension medications which were uniformly supplied by the government.
Study NCT01104376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
Study NCT01104376 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.~In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily.
Study NCT00797966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-34712
Description: Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
Study NCT00797966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
Study NCT00797966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADT
Description: Tablets, 10 - 225 mgs, dose once daily, 14 weeks
Study NCT00797966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ADT
Description: Tablets, 10 - 225 mgs, dose once daily, 14 weeks
Study NCT00732901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
Study NCT00732901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once daily days 1-28
Study NCT00732043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate extract
Description: 8 oz per day, 48 months
Study NCT00732043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: pomegranate juice
Description: 8 oz per day, 48 months
Study NCT00732043 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 8 oz per day, 48 months
Study NCT04280809 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GaAlAs laser
Description: GaAlAs laser (AMD Picasso, Dentsply Sirona, York, Pennsylvania, USA) with a wavelength of 810 nm was placed intraorally, at a distance of 1 cm in the position of the extracted tooth socket and circling in a 2 cm - diameter area. The power applied was 0.5 ± 20% W, continuously for 30 s. The total real energy released was 12.8 J and the real energy density applied was 4 J/cm2. Each patient was irradiated 3 times consecutively right after surgery, day 1 and day 2 after surgery
Study NCT04374227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment
Description: Body regions that were treated included head, cervical, thoracic, ribs, lumbar, pelvis, sacrum, lower extremity, and upper extremity.
Study NCT01031420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single arm dose dense MVAC
Description: standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
Study NCT05441878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% albumin
Description: Albumin arm for resuscitation fluid
Study NCT05441878 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balanced salt solution
Description: Only Balanced salt solution will be used.
Study NCT05441878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Balanced salt solution
Description: Only Balanced salt solution will be used.
Study NCT00560521 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
Study NCT03105544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulation-based training
Description: As described under group descriptions
Study NCT03175055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phoenix
Description: The study to assess safety and efficacy of Phoenix medical exoskeleton.
Study NCT02840084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen(TM) Ultrasound System
Description: Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.~The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts.
Study NCT01331213 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pregabalin
Description: FDA approved medication (capsules) at 200mg dose.
Study NCT01331213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT00422513 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta
Description: 120-360 micrograms intravenous (iv) monthly, starting dose
Study NCT00422513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin alfa
Description: As prescribed, iv, 3 times weekly
Study NCT03897439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Description: Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
Study NCT03897439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: Participants will receive the 24-hour 21mg nicotine patch for up to 18 weeks of treatment.
Study NCT03897439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline Tartrate
Description: VAR will be dispensed 0.5 mg once daily on Days 1-3, 0.5 mg twice daily on Days 4-7, and 1 mg twice daily from Day 8 through the end of treatment.
Study NCT03897439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion
Description: BUP will be dispensed 150 mg once daily on Days 0-3 and then 150 mg twice daily from Day 4 through optimization or the end of treatment.
Study NCT06531967 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT00289913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: PedvaxHIB™
Description: PedvaxHIB™ (Haemophilus B Conjugate Vaccine \[Meningococcal Protein Conjugate\]).~One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit.
Study NCT03262311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoxia marker
Description: Single oral dose of pimonidazole 500 mg/m2
Study NCT00565929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile saline (0.9%).
Study NCT00997516 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SILS appendectomy
Description: Use of SILSPort to perform laparoscopic appendectomy
Study NCT00997516 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional laparoscopic appendectomy
Description: conventional laparoscopic removal of the appendix
Study NCT00565929 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA-BN
Description: The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10\^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10\^7 or 1X10\^8 TCID 50.
Study NCT00443196 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MiCK Assay
Description: Physician determined treatment
Study NCT03999775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium, vitamin D and bioactive collagen peptides supplement
Study NCT03999775 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Calcium and vitamin D supplement
Study NCT02198001 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
Description: BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10
Study NCT02198001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
Description: BPs per os\< 3ans: amoxicillin- clavulanate J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~amoxicillin- clavulanate J-3 à J+10~In case of allergy:~BPs per os: clindamycine J-1 à J+10~BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):~clindamycine J-3 à J+10
Study NCT02198001 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: atraumatic extraction
Description: Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
Study NCT02198001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atraumatic extraction
Description: Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprorelin
Description: LHRH agonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin
Description: LHRH agonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin
Description: LHRH agonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: LHRH agonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin
Description: LHRH agonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: LHRH agonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Degarelix
Description: LHRH antagonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: LHRH antagonist
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bicalutamide
Description: Antiandrogen
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide
Description: Antiandrogen
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flutamide
Description: Antiandrogen
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flutamide
Description: Antiandrogen
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maximum androgen blockade
Description: Combination therapy with LHRH agonist and antiandrogen
Study NCT04248621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maximum androgen blockade
Description: Combination therapy with LHRH agonist and antiandrogen
Study NCT03838094 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biodentine
Description: it is a dentin substitute, a new biologically active material facilitates its penetration through opened dentinal tubules to crystallize interlocking with dentin and provide mechanical properties.
Study NCT03838094 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MTA
Description: MTA is a powder that consists of fine hydrophilic particles that set in the presence of moisture. MTA consists of tricalcium silicate, tricalcium aluminate, tricalcium oxide and silicate oxide. MTA was considered a remarkable biocompatible material with various clinical applications that include surgical and non-surgical applications such as pulp capping
Study NCT04061135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Response Inhibition and Deep Brain Stimulation in Parkinson's disease
Description: After creation of the burr hole and prior to DBS electrode placement, 1-2 subdural strip electrodes will be placed anteriorly or posteriorly from the cranial opening. These electrodes are routinely placed using this technique for seizure mapping, with arrays of electrodes (up to 6) being placed around the perimeter of the opening.14 Subdural strips vary in length and contact size (e.g., the 6-contact Ad-Tech strip), and are currently placed predominantly for studies of sensorimotor function,13 including at our institution (IRB-140327003). Placement over prefrontal areas is performed at other institutions.11-13 The DBS surgery will then proceed according to routine practice, and following lead placement in the optimal desired location, the research task paradigm will begin.
Study NCT04211220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A decision support software
Description: Insulin pump Continuous glucose monitoring
Study NCT03526588 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood
Description: 6×10\^6 mononuclear cells isolated from the patient's own umbilical cord blood per dose. 4 total doses administered intravenously over 7 days.
Study NCT01871480 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A:cytokine-induced killer cell +gefitinib
Description: CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
Study NCT01871480 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B:Gefitinib
Description: Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
Study NCT04042246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Information Provision
Description: Provide the information on the importance of the vaccination and tailored vaccination schedule
Study NCT00511940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acamprosate
Description: 999 mg/day - 2997 mg/day, oral
Study NCT00511940 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral, placebo
Study NCT02068898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XS003
Study NCT02068898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasigna
Study NCT01260675 — intervention group
Intervention type: DRUG
Intervention: Buprenorphine HCl/Naloxone HCl
Study NCT00766753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic vaccine pulsed with multiple peptides
Description: Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
Study NCT00766753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The first booster vaccine phase:
Description: This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
Study NCT00766753 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: The second booster vaccine phase:
Description: At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.~2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays
Study NCT02192424 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin alone
Study NCT02192424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Intermittent Insulin Therapy
Study NCT01191567 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VAC treatment
Description: wound treatment with VAC-therapy
Study NCT01191567 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: wound treatment with conventional treatment according to the hospitals local routines
Study NCT00329901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACWY conjugate vaccine (MenACWY-CRM)
Study NCT00329901 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)